In This Section

Program

Please Note: All session times for the AACR Virtual Annual Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application are U.S. Eastern Daylight Time (EDT).

Monday, August 17, 2020

Tuesday, August 18, 2020

Wednesday, August 19, 2020

Monday, August 17, 2020

Welcome and Opening Keynote
10:30–11:15 a.m.

Welcome and Keynote Introductions
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Rogue clones of self-reactive B cells with lymphoma driver mutations: A view of lymphoma precursors 
Christopher Goodnow, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Discussion / Q&A

Break
11:15–11:30 a.m.
Session 1: Teaching T-Cells New Tricks: Why Immunotherapy Fails in Lymphoma and How Do We Fix It?
Moderator: Helen E. Heslop, Baylor College of Medicine, Houston, Texas
11:30 a.m.–1:05 p.m.

Introduction
Helen E. Heslop

Title to be announced
Karin Tarte, Université de Rennes, Rennes, France

Immune exhaustion and immune suppression in lymphoma
Stephen M. Ansell, Mayo Clinic College of Medicine, Rochester, Minnesota

Optimizing immunostimulatory antibodies for cancer immunotherapy
Mark Cragg, University of Southampton, Southampton, United Kingdom

Title to be announced
Christian Steidl, BC Cancer, Vancouver, BC, Canada

Discussion / Q&A

Break
1:05–1:20 p.m.
Session 2: WHO vs. How? Changing Paradigms in Lymphoma Classification
Moderator: Georg Lenz, University of Münster, Münster, Germany
1:20–2:55 p.m.

Introduction
Moderator to be announced

Microenvironmental signatures reveal biological subtypes of DLBCL
Leandro C. Cerchietti, Weill Cornell Medical College, New York, New York

Molecular classification of diffuse large B-cell lymphoma
Bjoern Chapuy, University of Göttingen, Göttingen, Germany

Molecular classification of T-cell lymphomas
Keisuke Kataoka, National Cancer Center, Japan, Tokyo, Japan

The role of gene expression in the classification of aggressive B-cell lymphoma
David W. Scott, BC Cancer, Vancouver, BC, Canada

Discussion / Q&A

Break
2:55–3:10 p.m.
Session 3: Towards a Better Understanding of Adolescent Young Adult Lymphoma
Moderator: Sonali M. Smith, University of Chicago, Chicago, Illinois
3:10–4:20 p.m.

Introduction
Sonali M. Smith

Title to be announced
Lisa G. Giulino-Roth, Weill Cornell Medical College, New York, New York

AYA lymphomas: Bridging the divide
Kara Kelly, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Unique features of pediatric-type follicular lymphoma
Abner Louissaint, Massachusetts General Hospital, Boston, Massachusetts

Discussion / Q&A

Session 4: How Aberrant Metabolism Fuels Lymphoma
Moderator: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland
3:10–4:20 p.m.

Introduction
Francesco Bertoni

Oncogenic Rag GTPase signaling links cellular nutrients with FL microenvironment
Alejo Efeyan, Spanish National Cancer Research Center, CNIO, Madrid, Spain

Metabolic control of lymphomagenesis
Andrew Michael Intlekofer, Memorial Sloan Kettering Cancer Center, New York, New York

Additional speaker to be announced

Discussion / Q&A

Tuesday, August 18, 2020

Session 5: New CARs and Fine-Tuning Patient Selection for Therapy
Moderator to be announced
10–11:35 a.m.

Introduction
Moderator to be announced

CARs and armored CARs: Improving CAR T cell therapy for cancer
Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, New York

CAR T-cells for T-cell lymphoma
Maksim Mamonkin, Baylor College of Medicine, Houston, Texas

Determinants of CAR-T outcomes: Host, tumor, and product
Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Additional speaker to be announced

Discussion / Q&A

Break
11:35–11:50 a.m.
Session 6: Biology-Based Clinical Trials: A Myth or Hope for Reality?
Moderator: John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
11:50 a.m.–1:25 p.m.

Introduction
John F. Seymour

Can we hope for success in biologically stratified DLBCL studies?
Andrew John Davies, University of Southampton School of Medicine, Southampton, United Kingdom

Title to be announced
Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, New York

Precision treatment of lymphoma using genomics
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

Additional speaker to be announced

Discussion / Q&A

Break
1:25–1:40 p.m.
Session 7: Hacking the Lymphoma Epigenome to Create Better Therapies
Moderator: Ari M. Melnick, Weill Cornell Medical College, New York, New York
1:40–3:15 p.m.

Introduction
Ari. M. Melnick

The role of EZH2 gain-of-function mutations in lymphoma
Wendy Béguelin, Weill Cornell Medical College, New York, New York

Cooperative epigenetic interactions in normal and transformed germinal center B cells
Laura Pasqualucci, New York Presbyterian Hospital Herbert Irving Comprehensive Cancer Center, New York, New York

The epigenetic architecture of follicular lymphoma
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

What do the results from the trials tell us?
Peter W.M. Johnson, University of Southampton, Southampton, United Kingdom

Discussion / Q&A

Break
3:15–3:30 p.m.
Session 8: Cancer Health Disparities in Lymphoma: How Do We Improve Outcomes?
Moderator: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
3:30–4:40 p.m.

Introduction
Christopher R. Flowers

Risk disparities in lymphoid cancers: What we know and what we don’t
Wendy Cozen, USC Norris Comprehensive Cancer Center, Los Angeles, California

Cancer health disparities in lymphoma
Theresa H. M. Keegan, University of California Davis, Sacramento, California

Title to be announced
Christopher R. Flowers

Discussion / Q&A

Session 9: Hitting Back at MYC/BCL2 Lymphomas
Moderator: David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts
3:30–4:40 p.m.

Introduction
David M. Weinstock

Mouse model systems of double-hit lymphomas
Dinis Calado, London Research Institute, London, United Kingdom

Modeling and targeting double-hit lymphoma
Bruno Amati, European Institute of Oncology, Milan, Italy

Targeting BCL-2 with Venetoclax
Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, Massachusetts

Discussion / Q&A

Wednesday, August 19, 2020

Session 10: Dissecting Lymphoma Cell by Cell: A Dynamic Tale
Moderator: Kojo Elenitoba-Johnson, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
10–11:35 a.m.

Introduction
Kojo Elenitoba-Johnson

Resolving clonal variation and cellular tumor microenvironmental interactions in the B-cell lymphoma with single-cell genomics
Hanlee P. Ji, Stanford University, Stanford, California

Pathology from the atomic scale on up
Garry P. Nolan, Stanford Hospital, Stanford, California

Follicular lymphoma dynamics through single-cell analysis
Bertrand Nadel, Centre d’Immunologie de Marseille-Luminy, Marseille, France

Characterizing the tumor ecosystem in follicular lymphoma by CyTOF
Andrew P. Weng, BC Cancer, Vancouver, BC, Canada

Discussion / Q&A

Break
11:35–11:50 a.m.
Session 11: Can We Find and Destroy Lymphoma Precursor Cells?
Moderator: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas
11:50 a.m.–1:25 p.m.

Introduction
Michael R. Green

Tracking precursor stages of follicular lymphoma development
Sandrine Roulland, Centre d’Immunologie de Marseille-Luminy, Marseille, France

Defining lymphoma reservoirs: Clues from the genomics
Jessica Okosun, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Title to be announced
Zachary R. Hunter, Dana-Farber Cancer Institute, Boston, Massachusetts

Defining precursors in low-grade lymphomas that seed second lymphomas
David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts

Discussion / Q&A

Break
1:25–1:40 p.m.
Session 12: Using Liquid Biopsies for Real-Time Monitoring of Lymphoma Biology and Clinical Decision-Making
Moderator: David W. Scott, BC Cancer, Vancouver, BC, Canada
1:40–3:15 p.m.

Introduction
David W. Scott

Approaches for personalized medicine in lymphoma through liquid biopsies
David M. Kurtz, Stanford University, Stanford, California

Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA
Ryan D. Morin, Simon Fraser University, Burnaby, BC, Canada

Qualification and quantification of lymphoma under therapy by ctDNA analysis
Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

ctDNA in indolent lymphoid cancers treated with targeted therapies
Constantine S. Tam, St. Vincent’s Hospital Sydney, East Melbourne, Australia

Discussion / Q&A

Break
3:15–3:30 p.m.
Session 13: Preclinical Models: How to Best Predict Therapeutic Response
Moderator to be announced
3:30–4:55 p.m.

Introduction
Moderator to be announced

Developing preclinical models for peripheral T-cell lymphomas
Teresa Palomero, Columbia University, New York, New York

Use of genetic and molecular profiling to predict therapeutic response in dogs with B-cell lymphoma
Luca Aresu, University of Turin, Turin, Italy

Patient-derived tumor xenograft of human lymphomas
Giorgio Inghirami, Weill Cornell Medicine, New York, New York

Lymphoma organoids to study cooperative signaling and therapeutic resistance in human DLBCLs
Ankur Singh, Georgia Institute of Technology, Atlanta, Georgia

Discussion / Q&A

Session 14: Understanding and Targeting Aberrant Receptor Signaling in Lymphoma
Moderator: Louis M. Staudt, National Cancer Institute, Bethesda, Maryland
3:30–4:40 p.m.

Introduction
Moderator to be announced

New insights into the mechanisms of lymphoma evasion from BCR dependence
Stefano Casola, The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy

B-cell receptor–driven metabolism reprogramming
Benjamin Gewurz, Brigham & Women’s Hospital, Boston, Massachusetts

Additional speaker to be announced

Discussion / Q&A

Break
4:55–5:10 p.m.
Keynote Address and Closing Remarks
5:10–6 p.m.

Keynote Introduction
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Cellular and molecular control of germinal center B cell selection
Gabriel Victora, The Rockefeller University, New York, New York

Discussion / Q&A

Closing Remarks